Drug-target residence time and its implications for lead optimization
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromolecules by low-molecular-mass drugs. The binding of drugs to their macromolecular targets is therefore seen as paramount for pharmacological activity. In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC(50) or K(d). This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex. We describe the potential advantages of long residence time in terms of duration of pharmacological effect and target selectivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The translation between slow inhibitor binding kinetics and sustained pharmacodynamic modulation has been studied for a numberoftarget classes (58).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [58]
In the citing paper
“Furthermore, the targets of infectious diseases usually have high replication rates, while covalent inhibitors tend to have long residence times making them less effective in this area [128].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [128]
In the citing paper
“Furthermore, longer residence times of drugs with their targets, as a result of slower off-rates, is a useful mechanism to extend in-vivo efficacy (59–61).”
From A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit (2026) · cites this paper as [59]
Citations
Cites
Catalysis in chemistry and enzymology
Jencks, W. P. (1969) · Medical Entomology and Zoology · Cited by 3,217
Structure and Mechanism in Protein Science
Fersht, A. (1998) · Cited by 1,882
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Self-citationLiang, J., Woodward, C., & Edelsbrunner, H. (1998) · Protein Science · doi:10.1002/pro.5560070905 · Cited by 1,057
Enzymes: a practical introduction to structure, mechanism, and data analysis
(2001) · Choice Reviews Online · doi:10.5860/choice.38-3881 · Cited by 1,056
Optical biosensors in drug discovery
Cooper, M. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd838 · Cited by 1,015
Oppenheimer, N. J., & James, T. L. (1989) · Academic Press eBooks · Cited by 820
Rusnak, D. W., Lackey, K. E., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., et al. (2001) · PubMed · Cited by 728
Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis
Copeland, R. A. (2000) · Wiley eBooks · doi:10.1002/0471220639 · Cited by 726
Self-citation
Cited by
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
The cellular thermal shift assay for evaluating drug target interactions in cells
Jafari, R., Almqvist, H., Axelsson, H., Ignatushchenko, M., Lundbäck, T., Nordlund, P., & Molina, D. M. (2014) · Nature Protocols · doi:10.1038/nprot.2014.138 · Cited by 1,474
Role of Molecular Dynamics and Related Methods in Drug Discovery
De Vivo, M., Masetti, M., Bottegoni, G., & Cavalli, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01684 · Cited by 1,297
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865
From carbohydrate leads to glycomimetic drugs
Ernst, B., & Magnani, J. L. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2852 · Cited by 820
The drug–target residence time model: a 10-year retrospective
Copeland, R. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.18 · Cited by 722
Self-citationPotent inhibition of DOT1L as treatment of MLL-fusion leukemia
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-497644 · Cited by 722
Self-citationMolecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
Salo-Ahen, O. M. H., Alanko, I., Bhadane, R., Bonvin, A. M. J. J., Honorato, R. V., Hossain, S., Juffer, A. H., Kabedev, A., Lahtela-Kakkonen, M., Larsen, A. S., et al. (2020) · Processes · doi:10.3390/pr9010071 · Cited by 659
Ligand binding assays at equilibrium: validation and interpretation
Hulme, E. C., & Trevethick, M. A. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00604.x · Cited by 657
Protein structure-based drug design: from docking to molecular dynamics
Śledź, P., & Caflisch, A. (2018) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2017.10.010 · Cited by 565
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 587
Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective
Saikia, S., & Bordoloi, M. (2019) · Current Drug Targets · doi:10.2174/1389450119666181022153016 · Cited by 571
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
Tummino, P. J., & Copeland, R. A. (2008) · Biochemistry · doi:10.1021/bi8002023 · Cited by 544
Self-citationProbing the links between in vitro potency, ADMET and physicochemical parameters
Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3367 · Cited by 503
Survey of the year 2003 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.726 · Cited by 505
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frödin, M., & Taunton, J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.925 · Cited by 493
Ensemble Docking in Drug Discovery
Amaro, R. E., Baudry, J., Chodera, J., Demir, Ö., McCammon, J. A., Miao, Y., & Smith, J. C. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.02.038 · Cited by 479
Crystal Structure of an LSD-Bound Human Serotonin Receptor
Wacker, D., Wang, S., McCorvy, J. D., Betz, R. M., Venkatakrishnan, A. J., Levit, A., Lansu, K., Schools, Z. L., Che, T., Nichols, D. E., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.033 · Cited by 457
Drug–target residence time: critical information for lead optimization
Lu, H., & Tonge, P. J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.176 · Cited by 432
Conus Venom Peptide Pharmacology
Lewis, R. J., Dutertre, S., Vetter, I., & Christie, M. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005322 · Cited by 424
Prolonged and tunable residence time using reversible covalent kinase inhibitors
Bradshaw, J. M., McFarland, J. M., Paavilainen, V. O., Bisconte, A., Tam, D., Phan, V. T., Romanov, S., Finkle, D., Shu, J., Patel, V., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1817 · Cited by 422
Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
Hann, M. M., & Keserü, G. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3701 · Cited by 411
Biophysics in drug discovery: impact, challenges and opportunities
Renaud, J.-P., Chung, C.-W., Danielson, U. H., Egner, U., Hennig, M., Hubbard, R. E., & Nar, H. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.123 · Cited by 382
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate
Roy, M. J., Winkler, S., Hughes, S. J., Whitworth, C., Galant, M., Farnaby, W., Rumpel, K., & Ciulli, A. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00092 · Cited by 386
The experimental power of FR900359 to study Gq-regulated biological processes
Schrage, R., Schmitz, A.-L., Gaffal, E., Annala, S., Kehraus, S., Wenzel, D., Büllesbach, K. M., Bald, T., Inoue, A., Shinjo, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms10156 · Cited by 368
Molecular determinants of drug–receptor binding kinetics
Pan, A. C., Borhani, D. W., Dror, R. O., & Shaw, D. E. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.02.007 · Cited by 373
Sun, H., Duan, L., Chen, F., Liu, H., Wang, Z., Pan, P., Zhu, F., Zhang, J. Z. H., & Hou, T. (2018) · Physical Chemistry Chemical Physics · doi:10.1039/c7cp07623a · Cited by 372
Nanovehicular Intracellular Delivery Systems
Prokop, A., & Davidson, J. M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21270 · Cited by 363
Kinetics of protein–ligand unbinding: Predicting pathways, rates, and rate-limiting steps
Tiwary, P., Limongelli, V., Salvalaglio, M., & Parrinello, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424461112 · Cited by 347
New agents for the treatment of drug-resistant Mycobacterium tuberculosis
Hoagland, D. T., Liu, J., Lee, R. B., & Lee, R. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.026 · Cited by 328
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Barf, T., & Kaptein, A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3003203 · Cited by 331
Kang, L., Chung, B. G., Langer, R., & Khademhosseini, A. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.003 · Cited by 325
Covalent inhibitors design and discovery.
De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.019 · Cited by 315
Fan, J., & de Lannoy, I. A. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.007 · Cited by 309
Thermodynamics and Kinetics of Drug-Target Binding by Molecular Simulation
Decherchi, S., & Cavalli, A. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00534 · Cited by 301
Drug–Target Kinetics in Drug Discovery
Tonge, P. J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00185 · Cited by 287
Formation and signaling actions of electrophilic lipids
Schopfer, F. J., Cipollina, C., & Freeman, B. A. (2011) · Chemical Reviews · doi:10.1021/cr200131e · Cited by 299
Selectively Nonselective Kinase Inhibition: Striking the Right Balance
Morphy, R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901132v · Cited by 292
Long‐lasting target binding and rebinding as mechanisms to prolong in vivo drug action
Vauquelin, G., & Charlton, S. J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00936.x · Cited by 298
Protein conformational flexibility modulates kinetics and thermodynamics of drug binding
Amaral, M., Kokh, D. B., Bomke, J., Wegener, A., Buchstaller, H. P., Eggenweiler, H. M., Matias, P., Sirrenberg, C., Wade, R. C., & Frech, M. (2017) · Nature Communications · doi:10.1038/s41467-017-02258-w · Cited by 291
Yuthavong, Y., Tarnchompoo, B., Vilaivan, T., Chitnumsub, P., Kamchonwongpaisan, S., Charman, S. A., McLennan, D. N., White, K. L., Vivas, L., Bongard, E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204556109 · Cited by 277
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
Okamoto, K., Ikemori-Kawada, M., Jestel, A., von König, K., Funahashi, Y., Matsushima, T., Tsuruoka, A., Inoue, A., & Matsui, J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500394m · Cited by 285
PTH receptor-1 signalling—mechanistic insights and therapeutic prospects
Cheloha, R. W., Gellman, S. H., Vilardaga, J.-P., & Gardella, T. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.139 · Cited by 265
Schwartz, P. A., Kuzmic, P., Solowiej, J., Bergqvist, S., Bolanos, B., Almaden, C., Nagata, A., Ryan, K., Feng, J., Dalvie, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313733111 · Cited by 281
Target engagement and drug residence time can be observed in living cells with BRET
Robers, M. B., Dart, M. L., Woodroofe, C. C., Zimprich, C. A., Kirkland, T. A., Machleidt, T., Kupcho, K. R., Levin, S., Hartnett, J. R., Zimmerman, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms10091 · Cited by 274
Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity
Glukhova, A., Thal, D. M., Nguyen, A. T., Vecchio, E. A., Jörg, M., Scammells, P. J., May, L. T., Sexton, P. M., & Christopoulos, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.042 · Cited by 275
Krishnan, S., Miller, R. M., Tian, B., Mullins, R. D., Jacobson, M. P., & Taunton, J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505194w · Cited by 260
Prediction of drug–ABC-transporter interaction — Recent advances and future challenges
Montanari, F., & Ecker, G. F. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.03.001 · Cited by 257
Crawford, J. J., Johnson, A. R., Misner, D. L., Belmont, L. D., Castanedo, G., Choy, R., Coraggio, M., Dong, L., Eigenbrot, C., Erickson, R., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01712 · Cited by 257
Spectral gap optimization of order parameters for sampling complex molecular systems
Tiwary, P., & Berne, B. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600917113 · Cited by 259
A safe lithium mimetic for bipolar disorder
Singh, N., Halliday, A. C., Thomas, J. M., Kuznetsova, O. V., Baldwin, R., Woon, E. C. Y., Aley, P. K., Antoniadou, I., Sharp, T., Vasudevan, S. R., et al. (2013) · Nature Communications · doi:10.1038/ncomms2320 · Cited by 258
Inhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway
Lu, H., & Tonge, P. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700156e · Cited by 254
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
Chaikuad, A., M C Tacconi, E., Zimmer, J., Liang, Y., Gray, N. S., Tarsounas, M., & Knapp, S. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1629 · Cited by 242
Cramer, J., Sager, C. P., & Ernst, B. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00179 · Cited by 240
Vauquelin, G., & Charlton, S. J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12106 · Cited by 231
Gossert, A. D., & Jahnke, W. (2016) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2016.09.001 · Cited by 228
Kinetics for Drug Discovery: an industry-driven effort to target drug residence time
Schuetz, D. A., de Witte, W. E. A., Wong, Y. C., Knasmueller, B., Richter, L., Kokh, D. B., Sadiq, S. K., Bosma, R., Nederpelt, I., Heitman, L. H., et al. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.02.002 · Cited by 226
Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?
Liu, J. (., Lee, T., & DeFronzo, R. A. (2012) · Diabetes · doi:10.2337/db12-0052 · Cited by 225
Mechanistic enzymology in drug discovery: a fresh perspective
Holdgate, G. A., Meek, T. D., & Grimley, R. L. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.219 · Cited by 220
Self-citationHightower, K. E., Wang, R., DeAnda, F., Johns, B. A., Weaver, K., Shen, Y., Tomberlin, G. H., Carter, H. L., Broderick, T., Sigethy, S., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00157-11 · Cited by 226
Zhang, F., Wang, S., Yin, L., Yang, Y., Guan, Y., Wang, W., Xu, H., & Tao, N. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b02572 · Cited by 215
Menéndez-Arias, L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.01.007 · Cited by 207
Copeland, R. A. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003677725 · Cited by 209
Self-citationInhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain
Akçay, G., Belmonte, M. A., Aquila, B., Chuaqui, C., Hird, A. W., Lamb, M. L., Rawlins, P. B., Su, N., Tentarelli, S., Grimster, N. P., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2174 · Cited by 207
Unbinding Kinetics of a p38 MAP Kinase Type II Inhibitor from Metadynamics Simulations
Casasnovas, R., Limongelli, V., Tiwary, P., Carloni, P., & Parrinello, M. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b12950 · Cited by 211
Pharmacokinetics and the drug–target residence time concept
Dahl, G., & Akerud, T. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.02.010 · Cited by 204
Leproult, E., Barluenga, S., Moras, D., Wurtz, J.-M., & Winssinger, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101396q · Cited by 193
Teixobactin kills bacteria by a two-pronged attack on the cell envelope
Shukla, R., Lavore, F., Maity, S., Derks, M. G. N., Jones, C. R., Vermeulen, B. J. A., Melcrová, A., Morris, M. A., Becker, L. M., Wang, X., et al. (2022) · Nature · doi:10.1038/s41586-022-05019-y · Cited by 201
Xie, L., Xie, L., Kinnings, S. L., & Bourne, P. E. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134630 · Cited by 202
Conformational Adaptation in Drug–Target Interactions and Residence Time
Copeland, R. A. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.112 · Cited by 196
Self-citationEder, J. P., Shapiro, G. I., Appleman, L. J., Zhu, A. X., Miles, D., Keer, H., Cancilla, B., Chu, F., Hitchcock-Bryan, S., Sherman, L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0574 · Cited by 197
Shielded Hydrogen Bonds as Structural Determinants of Binding Kinetics: Application in Drug Design
Schmidtke, P., Luque, F. J., Murray, J. B., & Barril, X. (2011) · Journal of the American Chemical Society · doi:10.1021/ja207494u · Cited by 199
BioMedGPT: An Open Multimodal Large Language Model for BioMedicine
Luo, Y., Zhang, J., Fan, S., Yang, K., Hong, M., Wu, Y., Qiao, M., & Nie, Z. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3505955 · Cited by 225
Targeting Bacterial Central Metabolism for Drug Development
Murima, P., McKinney, J. D., & Pethe, K. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.020 · Cited by 189
Smith, A. J. T., Zhang, X., Leach, A. G., & Houk, K. N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800498e · Cited by 193
Naylor, M. R., Bockus, A. T., Blanco, M.-J., & Lokey, R. S. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.04.012 · Cited by 185
Target–drug interactions: first principles and their application to drug discovery
Núñez, S., Venhorst, J., & Kruse, C. G. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.013 · Cited by 181
Segala, E., Guo, D., Cheng, R. K. Y., Bortolato, A., Deflorian, F., Doré, A. S., Errey, J. C., Heitman, L. H., IJzerman, A. P., Marshall, F. H., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00653 · Cited by 184
Inceoglu, B., Bettaieb, A., Trindade da Silva, C. A., Lee, K. S. S., Haj, F. G., & Hammock, B. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510137112 · Cited by 184
Guo, D., Mulder‐Krieger, T., IJzerman, A. P., & Heitman, L. H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01897.x · Cited by 179
Soares, P., Gadd, M. S., Frost, J., Galdeano, C., Ellis, L., Epemolu, O., Rocha, S., Read, K. D., & Ciulli, A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00675 · Cited by 165
Erratum: Mechanistic enzymology in drug discovery: a fresh perspective
Holdgate, G. A., Meek, T. D., & Grimley, R. L. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.257 · Cited by 180
Self-citationAngst, D., Gessier, F., Janser, P., Vulpetti, A., Wälchli, R., Beerli, C., Littlewood-Evans, A., Dawson, J., Nuesslein-Hildesheim, B., Wieczorek, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01916 · Cited by 172
Luckner, S. R., Liu, N., am Ende, C. W., Tonge, P. J., & Kisker, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.090373 · Cited by 174
Acceleration of diabetic wound healing using a novel protease–anti-protease combination therapy
Gao, M., Nguyen, T. T., Suckow, M. A., Wolter, W. R., Gooyit, M., Mobashery, S., & Chang, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517847112 · Cited by 182
Kinetics of Drug Binding and Residence Time
Bernetti, M., Masetti, M., Rocchia, W., & Cavalli, A. (2019) · Annual Review of Physical Chemistry · doi:10.1146/annurev-physchem-042018-052340 · Cited by 173
International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update
IJzerman, A. P., Jacobson, K. A., Müller, C. E., Cronstein, B. N., & Cunha, R. A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000445 · Cited by 179
Jöst, C., Nitsche, C., Scholz, T., Roux, L., & Klein, C. D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006918 · Cited by 162
Heerding, D. A., Rhodes, N., Leber, J. D., Clark, T. J., Keenan, R. M., Lafrance, L. V., Li, M., Safonov, I. G., Takata, D. T., Venslavsky, J. W., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8004527 · Cited by 162
Self-citationLaRochelle, J. R., Fodor, M., Vemulapalli, V., Mohseni, M., Wang, P., Stams, T., LaMarche, M. J., Chopra, R., Acker, M. G., & Blacklow, S. C. (2018) · Nature Communications · doi:10.1038/s41467-018-06823-9 · Cited by 167
Drug‐Target Residence Time—A Case for G Protein‐Coupled Receptors
Guo, D., Hillger, J. M., IJzerman, A. P., & Heitman, L. H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21307 · Cited by 166
Xie, L., Evangelidis, T., Xie, L., & Bourne, P. E. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002037 · Cited by 165
Robertson, N. J., Jazayeri, A., Errey, J. C., Baig, A. H., Hurrell, E., Zhukov, A., Langmead, C. J., Weir, M., & Marshall, F. H. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.001 · Cited by 163
Protein conformational dynamics dictate the binding affinity for a ligand
Seo, M., Park, J., Kim, E., Hohng, S., & Kim, H. (2014) · Nature Communications · doi:10.1038/ncomms4724 · Cited by 161
Protein–Small Molecule Interactions in Native Mass Spectrometry
Bennett, J. L., Nguyen, G. T. H., & Donald, W. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00293 · Cited by 168
Protein-peptide association kinetics beyond the seconds timescale from atomistic simulations
Paul, F., Wehmeyer, C., Abualrous, E. T., Wu, H., Crabtree, M. D., Schöneberg, J., Clarke, J., Freund, C., Weikl, T. R., & Noé, F. (2017) · Nature Communications · doi:10.1038/s41467-017-01163-6 · Cited by 158
Metadata
- Authors
- Copeland, R. A., Pompliano, D. L., & Meek, T. D.
- Affiliations
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Copeland, Robert A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-08-04
- Volume
- 5
- Issue
- 9
- Pages
- 730-739
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2016408686
- Semantic Scholar
- 362824beb2008831aa65b4eb774e5c8703ff9c71
- Cited by
- 1,464
- References
- 46
- Citations by year
- 2026: 83 · 2025: 64 · 2024: 78 · 2023: 79 · 2022: 81 · 2021: 76 · 2020: 83 · 2019: 88 · 2018: 102 · 2017: 104 · 2016: 96 · 2015: 120 · 2014: 74 · 2013: 88 · 2012: 65
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
- Keywords
- drug-target residence time, lead optimization, drug selectivity, drug-target binding, binding affinity
- MeSH terms
- Binding, Competitive, Pharmaceutical Preparations, Humans, Kinetics, Ligands, Technology, Pharmaceutical, Drug Design, Drug Delivery Systems, Macromolecular Substances
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.